Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Extension for PF-ILD
NCT03820726Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in progressive fibrosing interstitial lung disease (PF-ILD), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Any Adverse Events up to 1195 days. Started Apr 2019; status: completed.
02
Drugs
nintedanib
03
Conditions
progressive fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT03820726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820726.